2014
DOI: 10.1016/j.ejogrb.2014.04.015
|View full text |Cite
|
Sign up to set email alerts
|

2009 A/H1N1 influenza vaccination in pregnancy: uptake and pregnancy outcomes – a historical cohort study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
54
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 40 publications
(55 citation statements)
references
References 28 publications
1
54
0
Order By: Relevance
“…29,37,41,45,48 In some studies a higher prevalence of underlying risk factors was detected among vaccinated women, which is not surprising as vaccination was primarily recommended in women with comorbidities. There are also numerous confounding characteristics that may increase the risk of preterm births and poor birth outcomes in general including maternal age, smoking, alcohol or drug use, previous history of preterm birth, socio-economic status and chronic diseases.…”
Section: Limitations Of the Observational Studiesmentioning
confidence: 97%
See 4 more Smart Citations
“…29,37,41,45,48 In some studies a higher prevalence of underlying risk factors was detected among vaccinated women, which is not surprising as vaccination was primarily recommended in women with comorbidities. There are also numerous confounding characteristics that may increase the risk of preterm births and poor birth outcomes in general including maternal age, smoking, alcohol or drug use, previous history of preterm birth, socio-economic status and chronic diseases.…”
Section: Limitations Of the Observational Studiesmentioning
confidence: 97%
“…37,39,46 Data on fetal safety of A/H1N1pdm09 monovalent vaccines administered to pregnant women during the 2009/10 pandemic are available from the USA, 30,37 Canada, 43 Argentina, 29 Taiwan 38 and from several European countries. 10,27,31,32,36,40,41,45,48 Unadjuvanted vaccines were used in the North American studies, in France and a study in Taiwan. 30,37,38,40,43,48 The A/H1N1 MF56-adjuvanted formulation was evaluated in Argentina, Italy and the Netherlands.…”
Section: 27-49mentioning
confidence: 99%
See 3 more Smart Citations